Director, Division of Hematology/Oncology
Director, Personalized Cancer Medicine
Professor of Medicine, Cancer Biology and Pathology
Dr. Pao has developed a basic and translational research program that has made seminal contributions to the understanding of molecular mechanisms in lung cancer pathogenesis. His work has helped change the standard of care in lung cancer by identifying new molecular mechanisms of sensitivity and resistance of lung cancers to EGFR tyrosine kinase inhibitors. Dr. Pao’s research has yielded important insights into the molecular understanding of lung adenocarcinoma in never-smokers. Based on these discoveries, he has developed and successfully tested new anti-cancer therapies in animal models and humans.
Dr. Pao earned his M.D. and Ph.D. at Yale University and performed his housestaff training in Internal Medicine at New York Presbyterian Hospital-Weill Cornell Campus. He completed his medical oncology fellowship training at Memorial Sloan-Kettering Cancer Center.
Dr. Pao has authored and co-authored more than 140 research articles and reviews in peer-reviewed journals such as Nature, Nature Reviews Cancer, Journal of Clinical Investigation, Proceedings of the National Academy of Sciences, Public Library of Science (PLoS) Medicine, Journal of Clinical Oncology, Science Translational Medicine, Lancet Oncology, Cancer Discovery and Cancer Research. He has served as senior editor at Cancer Research, journal editor for PLoS Medicine and Clinical Cancer Research, and editor for the Journal of Clinical Oncology. He has reviewed grants for multiple organizations including study sections at NIH, CPRIT, ASCO’s Conquer Cancer Foundation, IASLC and the Uniting Against Lung Cancer Foundation.
Dr. Pao has received an ASCO Young Investigator Award, a Clinical Scientist Development Award from the Doris Duke Charitable Foundation, a V Foundation grant, the Hope Now Award from the Joan’s Legacy Foundation and an SU2C Innovative Grant Award from the AACR. He was inducted into the American Society for Clinical Investigation in 2011.
“I am dedicated to improving the care of cancer patients. The Diagnostic Mentor Team is one tool that will help change the standard of care for cancer”